Study Title: A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Christopher Rangel, at rangelc@musc.edu.Study Coordinator, Alec Schumpp, at schumpp@musc.edu.Trial opened at the following institutions: Medical University of South Carolina